Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial
Herman Depypere, D. Timmerman, Gilbert Donders, et al.
The Journal of Clinical Endocrinology & Metabolism (2019) Vol. 104, Iss. 12, pp. 5893-5905
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

The Menopause Transition: Signs, Symptoms, and Management Options
Nanette Santoro, Cassandra Roeca, Brandilyn A. Peters, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 106, Iss. 1, pp. 1-15
Open Access | Times Cited: 316
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
Samuel Lederman, Faith D Ottery, Antonio Cano, et al.
The Lancet (2023) Vol. 401, Iss. 10382, pp. 1091-1102
Closed Access | Times Cited: 145
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
Kimball A. Johnson, Nancy Martin, Rossella E. Nappi, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 8, pp. 1981-1997
Open Access | Times Cited: 112
The 2023 nonhormone therapy position statement of The North American Menopause Society
Chrisandra Shufelt, Vivien Brown, Janet S. Carpenter, et al.
Menopause The Journal of The North American Menopause Society (2023) Vol. 30, Iss. 6, pp. 573-590
Closed Access | Times Cited: 102
Management of menopause: a view towards prevention
Roger A. Lobo, Anne Gompel
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 457-470
Closed Access | Times Cited: 91
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause
Genevieve Neal-Perry, Antonio Cano, Samuel Lederman, et al.
Obstetrics and Gynecology (2023)
Open Access | Times Cited: 59
Synthesis and clinical application of new drugs approved by FDA in 2023
Yatao Wang, Pengcheng Yang, Yanfeng Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116124-116124
Closed Access | Times Cited: 17
FDA approved fluorine-containing drugs in 2023
Qian Wang, Yeping Bian, Gagan Dhawan, et al.
Chinese Chemical Letters (2024) Vol. 35, Iss. 11, pp. 109780-109780
Closed Access | Times Cited: 16
Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms
Artur Menegaz de Almeida, Paloma Oliveira, Lucca Moreira Lopes, et al.
Obstetrics and Gynecology (2025)
Closed Access | Times Cited: 3
“MANAGEMENT OF MENOPAUSAL HOT FLUSHES” RECOMMENDATIONS OF SPANISH MENOPAUSE SOCIETY
María Fasero, M Sanchez, Laura Baquedano, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology X (2025) Vol. 25, pp. 100366-100366
Open Access | Times Cited: 2
A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
Graeme L. Fraser, Samuel Lederman, Arthur Waldbaum, et al.
Menopause The Journal of The North American Menopause Society (2020) Vol. 27, Iss. 4, pp. 382-392
Open Access | Times Cited: 89
Fezolinetant in the treatment of vasomotor symptoms associated with menopause
Herman Depypere, Christopher Lademacher, Emad Siddiqui, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 7, pp. 681-694
Open Access | Times Cited: 61
Fezolinetant: First Approval
Arnold Lee
Drugs (2023) Vol. 83, Iss. 12, pp. 1137-1141
Closed Access | Times Cited: 22
Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause
Nicole E. Cieri‐Hutcherson, Elaine K. Marji, Timothy C. Hutcherson
Menopause The Journal of The North American Menopause Society (2024) Vol. 31, Iss. 4, pp. 342-354
Closed Access | Times Cited: 10
Alternative and non-hormonal treatments to symptoms of menopause
Veronica Djapardy, Nicholas Panay
Best Practice & Research Clinical Obstetrics & Gynaecology (2021) Vol. 81, pp. 45-60
Closed Access | Times Cited: 54
Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
Nanette Santoro, Arthur Waldbaum, Samuel Lederman, et al.
Menopause The Journal of The North American Menopause Society (2020) Vol. 27, Iss. 12, pp. 1350-1356
Open Access | Times Cited: 51
Menopause review: Emerging treatments for menopausal symptoms
Bijal Patel, Waljit S. Dhillo
Best Practice & Research Clinical Obstetrics & Gynaecology (2021) Vol. 81, pp. 134-144
Closed Access | Times Cited: 51
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause
Antonia Morga, Mayank Ajmera, Emily Gao, et al.
Menopause The Journal of The North American Menopause Society (2023) Vol. 31, Iss. 1, pp. 68-76
Open Access | Times Cited: 20
The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B
Bijal Patel, Kanyada Koysombat, Edouard Mills, et al.
Endocrine Reviews (2023) Vol. 45, Iss. 1, pp. 30-68
Open Access | Times Cited: 19
Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials
Antonio Cano, Rossella E. Nappi, Nanette Santoro, et al.
BJOG An International Journal of Obstetrics & Gynaecology (2024) Vol. 131, Iss. 9, pp. 1296-1305
Open Access | Times Cited: 7
Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2)
Nanette Santoro, Rossella E. Nappi, Genevieve Neal‐Perry, et al.
Menopause The Journal of The North American Menopause Society (2024) Vol. 31, Iss. 4, pp. 247-257
Open Access | Times Cited: 7
Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials
Syed Muhammad Muneeb Akhtar, Abraish Ali, Muhammad Sohaib Khan, et al.
International Journal of Gynecology & Obstetrics (2024) Vol. 166, Iss. 3, pp. 969-983
Closed Access | Times Cited: 6
Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
Graeme L. Fraser, Barbara Obermayer‐Pietsch, Joop S.E. Laven, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 106, Iss. 9, pp. e3519-e3532
Open Access | Times Cited: 40
The neuroendocrinology of the preoptic area in menopause: Symptoms and therapeutic strategies
Manish Modi, Waljit S. Dhillo
Handbook of clinical neurology (2021), pp. 455-460
Closed Access | Times Cited: 39
Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep
Marci English, Boyka Stoykova, Christina Slota, et al.
Journal of Patient-Reported Outcomes (2021) Vol. 5, Iss. 1
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top